Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 14/20 | 0.87 |
| ▸ | RAF1 | P04049 | 9/20 | 0.87 |
| ▸ | KDR | P35968 | 5/20 | 0.87 |
| ▸ | LCK | P06239 | 3/20 | 0.87 |
| ▸ | FYN | P06241 | 3/20 | 0.87 |
| ▸ | PDGFRB | P09619 | 3/20 | 0.87 |
| ▸ | KIT | P10721 | 3/20 | 0.87 |
| ▸ | FLT1 | P17948 | 3/20 | 0.87 |
| ▸ | FLT4 | P35916 | 3/20 | 0.87 |
| ▸ | STK25 | O00506 | 1/20 | 0.87 |
| ▸ | CIT | O14578 | 1/20 | 0.87 |
| ▸ | EPHB6 | O15197 | 1/20 | 0.87 |
| ▸ | MAP3K7 | O43318 | 1/20 | 0.87 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.87 |
| ▸ | PAK3 | O75914 | 1/20 | 0.87 |
| ▸ | STK10 | O94804 | 1/20 | 0.87 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.87 |
| ▸ | ABL1 | P00519 | 1/20 | 0.87 |
| ▸ | CSF1R | P07333 | 1/20 | 0.87 |
| ▸ | YES1 | P07947 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Raf-265 SCHEMBL686452 | 0.93 | BRAF (1.00) | BRAFRAF1KDRLCKFYN | |
| Raf-265 SCHEMBL1562237 | 0.93 | BRAF (1.00) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL11996499 | 0.93 | BRAF (0.87) | BRAFRAF1KDRLCKFYN | |
| Raf-265 SCHEMBL29368571 | 0.93 | BRAF (1.00) | BRAFRAF1KDRLCKFYN | |
| Raf-265 SCHEMBL29355586 | 0.93 | BRAF (1.00) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL12811765 | 0.92 | BRAF (0.86) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL1435193 | 0.92 | BRAF (0.86) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL1435161 | 0.92 | BRAF (0.86) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL1435427 | 0.92 | BRAF (0.86) | BRAFRAF1KDRLCKFYN | |
| SCHEMBL19661215 | 0.92 | BRAF (0.91) | BRAFRAF1KDRLCKFYN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9241939-B2 | Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathway | NOVARTIS AG (CH) | 2016-01-26 | — | — | US | disclosed |
| US-20150105417-A1 | Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathway | GARCIA-ECHEVERRIA CARLOS (FR) | 2015-04-16 | — | — | US | disclosed |
| US-8962650-B2 | Therapeutic agent for tumor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-02-24 | — | — | US | disclosed |
| US-20140057904-A1 | Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathway | GARCIA-ECHEVERRIA CARLOS (FR) | 2014-02-27 | — | — | US | disclosed |
| US-20140031384-A1 | THERAPEUTIC AGENT FOR TUMOR | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-01-30 | — | — | US | disclosed |
| US-8501785-B2 | Salts of benzimidazolyl pyridyl ethers and formulations thereof | NOVARTIS AG (CH) | 2013-08-06 | — | — | US | disclosed |
| US-20120308651-A1 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF | NOVARTIS AG | 2012-12-06 | — | — | US | disclosed |
| US-20110301184-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR | NOVARTIS AG (CH) | 2011-12-08 | — | — | US | disclosed |
| US-20110281917-A1 | Substituted Benzimidazoles for the Treatment of Astrocytomas | NOVARTIS AG (CH) | 2011-11-17 | — | — | US | disclosed |
| US-20110105521-A1 | COMBINATION OF (A) A PHOSPHOINOSITIDE 3-KINASE INHIBITOR AND (B) A MODULATOR OF RAS/RAF/MEK PATHWAY | NOVARTIS AG (CH) | 2011-05-05 | — | — | US | disclosed |
| US-20110092546-A1 | SUBSTITUTED BENZIMIDAZOLES FOR NEUROFIBROMATOSIS | NOVARTIS AG | 2011-04-21 | — | — | US | disclosed |
| WO-2007030377-A1 | SUBSTITUTED BENZIMIDAZOLES AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2007-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092546-A1 | SUBSTITUTED BENZIMIDAZOLES FOR NEUROFIBROMATOSIS | VHL, NISCH, SDHA | BRAF 15/4885RAF1 421/4885KDR 538/4885 |
| US-20120308651-A1 | SALTS OF BENZIMIDAZOLYL PYRIDYL ETHERS AND FORMULATIONS THEREOF | PIR, BRD8, PHOSPHO1 | BRAF 542/4885RAF1 874/4885KDR 2799/4885 |
| US-20140031384-A1 | THERAPEUTIC AGENT FOR TUMOR | KRAS, TP53, HRAS | BRAF 53/4885RAF1 93/4885KDR 1270/4885 |
| US-20110281917-A1 | Substituted Benzimidazoles for the Treatment of Astrocytomas | IDH1, IDH2, IDH3B | BRAF 90/4885RAF1 1135/4885KDR 1130/4885 |
| US-20110105521-A1 | COMBINATION OF (A) A PHOSPHOINOSITIDE 3-KINASE INHIBITOR AND (B) A MODULATOR OF RAS/RAF/MEK PATHWAY | BRAF, RAF1, NRAS | BRAF 1/4885RAF1 2/4885KDR 551/4885 |
| US-20140057904-A1 | Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathway | BRAF, RAF1, NRAS | BRAF 1/4885RAF1 2/4885KDR 551/4885 |
| US-20150105417-A1 | Combination of (a) a phosphoinositide 3-kinase inhibitor and (b) a modulator of RAS/RAF/MEK pathway | BRAF, RAF1, NRAS | BRAF 1/4885RAF1 2/4885KDR 551/4885 |
| US-20110301184-A1 | PHARMACEUTICAL COMBINATIONS COMPRISING A MTOR INHIBITOR AND A RAF KINASE INHIBITOR | BRAF, RAF1, MTOR | BRAF 1/4885RAF1 2/4885KDR 539/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.